In adults with overweight and symptomatic knee osteoarthritis, liraglutide did not decrease serum NGAL more than placebo after 52 weeks (reported contrast 14.9 ng/mL; 95% CI -92.1 to 121.7; P = 0.78).
In plain wordsIn adults with overweight and knee osteoarthritis, liraglutide did not lower NGAL significantly more than placebo.
- Peptide
- Liraglutide
- Outcome
- No significant changeSerum NGAL change
- Study
n = 127
- Comparator
- Placebo
- Analysis
- Exploratory
- Outcome group
- Inflammation markers · Immune and inflammation
- Studied dose
- 3 mg/d · 52 weeksAs given in this study (human).
Measurements
- Serum NGAL difference
- 14.9 ng/ml
- liraglutide versus placebo; 95% CI -92.1 to 121.7 ng/mL; P = 0.78
Source sentences
52 weeks of treatment with either liraglutide or placebo, liraglutide did not cause a greater decrease in serum NGAL (14.9 ng/ml, 95%CI: -92.1 to 121.7 ng/mL, P = 0.78).
4 context sentences(design, population, supporting numbers)
A secondary analysis of a randomized, double-blinded, placebo-controlled trial in adults with overweight (BMI≥27 kg/m2) and symptomatic, early-to-moderate radiographic knee OA.
Participants who lost min. 5 % of initial bodyweight were randomized 1:1 to liraglutide 3 mg/d or placebo for 52 weeks.
168 participants were enrolled to the initial intensive diet intervention; 127 participants, with NGAL samples, were randomized.
Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.